Total submissions: 14
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Clin |
RCV000758035 | SCV000564433 | likely pathogenic | Hypertrophic cardiomyopathy | 2021-11-30 | reviewed by expert panel | curation | The NM_000257.4(MYH7):c.2608C>T (p.Arg870Cys) variant has been reported in >15 individuals with HCM (PS4; Anan 2000 PMID:10862102; Woo 2003 PMID:12975413; Uchiyama 2009 PMID:19149795; Funada 2010 PMID:20975235; Otsuka 2012 PMID:22112859; Fujita 2013 PMID: 24621997; Wang 2014 PMID:25132132; Mademont-Soler 2017 PMID:28771489; Hayashi 2018 PMID:29907873; Mak 2018 PMID:30022097; Inagaki 2018 PMID:30206291; GeneDx pers. comm.; LMM pers. comm.; OMGL pers. comm.). This variant segregated with disease in 2 affected individual with HCM from 2 families (Otsuka 2011 PMID 22112859; LMM pers. comm.); however, this data is currently insufficient to establish co-segregation with disease and apply PP1. This variant was identified in 0.0007% (FAF 95% CI; 3/113730) of European chromosomes in gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org/). This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be associated with HCM (Walsh 2017 PMID:27532257). Additionally, a different pathogenic missense variant has been previously identified at this codon which indicates that this residue may be critical to the function of the protein (PM5; NM_000257.4(MYH7):c.2609G>A (p.Arg870His) - Variation ID 14120). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for hypertrophic cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PS4, PM2, PM5, PP3. |
| Laboratory for Molecular Medicine, |
RCV000758035 | SCV000203913 | likely pathogenic | Hypertrophic cardiomyopathy | 2022-06-30 | criteria provided, single submitter | clinical testing | The p.Arg870Cys variant in MYH7 has been reported in at least 10 individuals with HCM (Anan 2000 PMID:10862102; Woo 2003 PMID:12975413; Uchiyama 2009 PMID:19149795; Funada 2010 PMID:20975235; Otsuka 2012 PMID:22112859; Fujita 2013 PMID: 24621997; Wang 2014 PMID:25132132; Mademont-Soler 2017 PMID:28771489; Hayashi 2018 PMID:29907873; Mak 2018 PMID:30022097; Inagaki 2018 PMID:30206291 LMM data) and segregated with disease in at least 2 affected relatives from 2 families (Otsuka 2012, LMM data). This variant has been identified in 6/251444 chromosomes by gnomAD (http://gnomad.broadinstitute.org) and was classified as likely pathogenic by the ClinGen Inherited Cardiomyopathy Expert Panel on 12/15/16 (Variation ID# 161326). Computational prediction tools and conservation analysis suggest that the p.Arg870Cys variant may impact the protein, and another variant at the same codon (p.Arg870His) is classified as pathogenic variant by our laboratory. In addition, this variant lies in the head region of the protein and missense variants in this region are statistically more likely to be disease-associated (Walsh 2016). In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PM1, PM2, PM5, PS4_Moderate, PP3. |
| Gene |
RCV000158554 | SCV000208489 | likely pathogenic | not provided | 2023-01-11 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Reported in ClinVar as likely pathogenic by the ClinGen Inherited Cardiomyopathy Variant Curation Expert Panel (ClinVar Variant ID# 161326); This variant is associated with the following publications: (PMID: 23447461, 27532257, 30022097, 23299917, 25637381, 25892673, 10862102, 12975413, 27247418, 20075948, 20975235, 25611685, 29300372, 30217213, 32286303, 36005429, 31447099, 32492895, 33407484, 33087929, 34542152, 34057638, 35456187, 29907873, 24621997, 22112859, 34428338, 36618848, 30206291, Kawano2021[CaseReport]) |
| Invitae | RCV000758035 | SCV000957373 | pathogenic | Hypertrophic cardiomyopathy | 2023-12-20 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 870 of the MYH7 protein (p.Arg870Cys). This variant is present in population databases (rs138049878, gnomAD 0.01%). This missense change has been observed in individuals with hypertrophic cardiomyopathy (PMID: 10862102, 12975413, 20975235, 22112859, 25132132, 27532257, 28771489, 30022097, 30206291). ClinVar contains an entry for this variant (Variation ID: 161326). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYH7 protein function with a positive predictive value of 95%. This variant disrupts the p.Arg870 amino acid residue in MYH7. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7796500, 9172070, 12974739, 17192269, 17703256). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| Color Diagnostics, |
RCV001189961 | SCV001357361 | likely pathogenic | Cardiomyopathy | 2023-10-16 | criteria provided, single submitter | clinical testing | This missense variant replaces arginine with cysteine at codon 870 in the neck and hinge (S2) domain of the MYH7 protein. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). This variant is found within a highly conserved region of the myosin head domain. Missense variants in this region have been shown to be significantly overrepresented in individuals with hypertrophic cardiomyopathy (PMID: 27532257). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in over 15 individuals affected with hypertrophic cardiomyopathy (PMID: 10862102, 12975413, 20975235, 22112859, 24621997, 27532257, 28771489, 29907873, 30022097, 32492895, 33407484, 33495596, 33495597). It has also been reported in an individual affected with restrictive cardiomyopathy (PMID: 29907873) and in an individual affected with neurally mediated syncope (PMID: 36005429). This variant has been identified in 6/251444 chromosomes in the general population by the Genome Aggregation Database (gnomAD). A different variant affecting the same codon, p.Arg870His, is considered to be disease-causing (ClinVar variation ID: 14120), suggesting that arginine at this position is important for MYH7 protein function. Based on the available evidence, this variant is classified as Likely Pathogenic. |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV000148707 | SCV001821483 | pathogenic | Primary familial hypertrophic cardiomyopathy | 2021-08-09 | criteria provided, single submitter | clinical testing | Variant summary: MYH7 c.2608C>T (p.Arg870Cys) results in a non-conservative amino acid change located in the Myosin tail domain (IPR002928) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 252156 control chromosomes. This variant occurs in the region enriched for HCM mutations (residues 181-937, Walsh_2017). c.2608C>T has been reported in the literature in multiple individuals affected with Hypertrophic Cardiomyopathy (example, Woo_2003, Anan_2000, Otsuka_2012, Wang_2014, Mak_2018, Inagaki_2018). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories and one expert panel (ClinGen Inherited Cardiomyopathy Variant Curation Expert Panel) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All submitters classified the variant as pathogenic (n=1)/likely pathogenic (n=5) citing overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as pathogenic. |
| 3billion | RCV001261972 | SCV002058162 | pathogenic | Hypertrophic cardiomyopathy 1 | 2022-01-03 | criteria provided, single submitter | clinical testing | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000161326, 3billion dataset, PS1_S). A different missense change at the same codon has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000014120, PM5_M). The variant is located in a well-established functional domain or exonic hotspot, where pathogenic variants have frequently reported (PM1_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.8, 3CNET: 0.963, PP3_P). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000024, PM2_M).Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. |
| Ambry Genetics | RCV002433640 | SCV002745213 | likely pathogenic | Cardiovascular phenotype | 2023-10-19 | criteria provided, single submitter | clinical testing | The p.R870C variant (also known as c.2608C>T), located in coding exon 20 of the MYH7 gene, results from a C to T substitution at nucleotide position 2608. The arginine at codon 870 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration is located in the myosin head domain, which contains a statistically significant clustering of pathogenic missense variants (Homburger JR et al. Proc Natl Acad Sci U S A, 2016 06;113:6701-6; Walsh R et al. Genet Med, 2017 02;19:192-203; Ambry internal data). This variant has been detected in several unrelated probands reported to have hypertrophic cardiomyopathy (HCM) (Anan R et al. Hum Mutat, 2000 Jun;15:584; Woo A et al. Heart, 2003 Oct;89:1179-85; Otsuka H et al. Circ J, 2012 Nov;76:453-61; Homburger JR et al. Proc Natl Acad Sci U S A, 2016 06;113:6701-6; Walsh R et al. Genet Med, 2017 02;19:192-203; Mak TSH et al. Sci Rep, 2018 Jul;8:10846; Hayashi T et al. J Hum Genet, 2018 Sep;63:989-996; Kim HY et al. J Clin Med, 2020 Jun;9). A different variant affecting this codon (p.R870H, c.2609G>A) has also been reported in association with HCM (Homburger JR et al. Proc Natl Acad Sci U S A, 2016 06;113:6701-6). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Fulgent Genetics, |
RCV002483292 | SCV002785113 | likely pathogenic | Hypertrophic cardiomyopathy 1; Myopathy, myosin storage, autosomal recessive; Myosin storage myopathy; Congenital myopathy with fiber type disproportion; Dilated cardiomyopathy 1S; MYH7-related skeletal myopathy | 2021-09-04 | criteria provided, single submitter | clinical testing | |
| Johns Hopkins Genomics, |
RCV001261972 | SCV003839057 | likely pathogenic | Hypertrophic cardiomyopathy 1 | 2022-09-13 | criteria provided, single submitter | clinical testing | This MYH7 variant (rs138049878) is rare (<0.1%) in a large population dataset (gnomAD: 6/251444 total alleles, 0.0024%, no homozygotes) and has been reported in ClinVar. This variant has previously been reported in unrelated individuals with CMH1 and was classified by the ClinGen Inherited Cardiomyopathy Expert Panel. This variant lies in the head region of the protein (aa 181-937) and missense variants in this region are statistically more likely to be associated with CMH1. Additionally, a different pathogenic missense variant, c.2609G>A (p.Arg870His), has been previously identified at this codon which indicates that this residue may be critical to the function of the protein. Two bioinformatic tools queried8 predict that this substitution would be damaging, and the arginine residue at this position is strongly conserved across the vertebrate species assessed. Bioinformatic analysis predicts that this missense variant would not affect normal exon 22 splicing, although this has not been confirmed experimentally to our knowledge. We consider c.2608C>T to be likely pathogenic. |
| Institute of Human Genetics Munich, |
RCV001261972 | SCV004045795 | pathogenic | Hypertrophic cardiomyopathy 1 | 2023-08-14 | criteria provided, single submitter | clinical testing | |
| CSER _CC_NCGL, |
RCV000148707 | SCV000190437 | uncertain significance | Primary familial hypertrophic cardiomyopathy | 2014-06-01 | no assertion criteria provided | research | |
| Stanford Center for Inherited Cardiovascular Disease, |
RCV000158554 | SCV000280329 | likely pathogenic | not provided | 2014-12-23 | no assertion criteria provided | clinical testing | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. Arg870Cys has been previously observed in association with hypertrophic cardiomyopathy (HCM) in at least 5 unrelated individuals, apparently with good segregation data in one family. Anan et al. (2000) found Arg870Cys in a 61-year-old man of Japanese descent with asymmetrical septal hypertrophy. It appears to have segregated with disease in 5 of his affected family members, but the language of the report is vague (“5 individuals in this family were affected with the mutation.”) The Seidman’s Harvard Sarcomere Protein Gene Mutation Database reports the variant in a male HCM patient with onset at age 13. Woo et al. (2003) found the variant in a Toronto proband with HCM and a family history of 4 other affecteds including 3 premature sudden deaths under the age of 60. Average age at diagnosis for this family was 45 years. No segregation data in affected family members was provided, although several unaffecteds were tested. Arg870Cys has also been observed in two other unrelated individuals tested for HCM at GeneDx, according to the report. Variation at this same locus has been associated with disease, most notably Arg870His which we categorize as very likely diseae causing. The Arg870His variant has been reported in at least 11 unrelated cases of HCM with strong segregation data in one SE-Asian Indian family (11 individuals), good segregation data in 2 additional families, and weak segregation data in two more. Structural and functional data are available. In total it had not been seen in ~5670 published controls and publicly available population datasets as of 1/15/2012. It is present in dbSNP as rs36211715 (“probable-pathogenic”), submitted by the Dept. of Genetics at Osmania University, and also by the OMIM staff at Johns Hopkins. Another variant at this site, Arg870Leu, was reported by the Harvard Sarcomere Protein Gene Mutation Database as a novel variant observed by the Seidman group in two members of one family who both had HCM. Variation at nearby codons of MYH7 (within 10 amino acids to either side) has also been associated with disease, supporting the functional importance of this region of the protein. These HCM variants include Ser866Tyr, Ala868Pro, Arg869Cys, Arg869Gly, Arg869His, and Met877Lys (Harvard Sarcomere Protein Gene Mutation Database; Human Gene Mutation Database as reported by GeneDx). This is a nonconservative amino acid change from a basic, positively-charged Arginine to a neutral, polar Cysteine. The Arginine at codon 870 is highly conserved across 40 vertebrate species examined (it is a lysine in 2 species: Stickleback and Tetraodon). Surrounding residues are also highly conserved. In silico analysis with PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) predicts the variant to be “probably damaging” and SIFT predicts it to be “deleterious”. This variant is in the rod domain of the beta-myosin heavy chain protein (Rayment et al. 1995) localized to the coiled-coil alpha-helical S-2 region (Cuda et al. 1997). In total the Arg870Cys variant been seen in 1 out of ~6850 individuals from published controls and publicly available population datasets. It is present in 1/4300 Caucasian individuals and 0/2200 African American individuals in the NHLBI Exome Sequencing Project dataset (as of 11/16/2012). It is listed in dbSNP as rs138049878, and was submitted by NHLBI-ESP. It is not present in 1000 genomes (as of 11/16/2012). Anan et al. (2000) did not find it in at least 50 control individuals of unspecified ancestry, who were likely Japanese to match the affecteds. Woo et al. (2003) did not find it in 106 control individuals. It was not present in up to 200 control individuals of Caucasian and African-American ancestry tested at GeneDx. |
| Equipe Genetique des Anomalies du Developpement, |
RCV001261972 | SCV001439329 | likely pathogenic | Hypertrophic cardiomyopathy 1 | 2020-09-22 | no assertion criteria provided | clinical testing |